Corporate Member Update: Pfizer-BAVENCIO®
Corporate Member Update: Pfizer-BAVENCIO®
BAVENCIO®
July, 2020
Pfizer is pleased to announce that on June 30, 2020 the U.S. Food and Drug Administration (FDA) approved BAVENCIO® (avelumab) Injection 20 mg/mL for a new indication. BAVENCIO is co-developed and co-commercialized by EMD Serono and Pfizer Inc.
Please refer to the revised Full Prescribing Information for BAVENCIO.